Page last updated: 2024-08-21

pyrazines and Astrocytoma

pyrazines has been researched along with Astrocytoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Andrews, D; Curran, WJ; Dicker, AP; Kubicek, GJ; Machtay, M; Mallon, G; Myers, T; Ramirez, M; Werner-Wasik, M	1
Ahnert, P; Bauer, M; Ganten, TM; Haas, TL; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Sprick, MR; Sykora, J; Walczak, H	1
Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F	1

Trials

1 trial(s) available for pyrazines and Astrocytoma

Article	Year
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome	2009

Article

Year

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies.

International journal of radiation oncology, biology, physics, 2009, Jun-01, Volume: 74, Issue:2

Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Male; Middle Aged; Pyrazines; Radiotherapy; Temozolomide; Treatment Outcome

2009

Other Studies

2 other study(ies) available for pyrazines and Astrocytoma

Article	Year
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Female; Humans; Immunotherapy; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand	2007
Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21 Topics: Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Humans; Immunotherapy; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand	2007

Article

Year

Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11

Topics: Adolescent; Adult; Aged; Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Female; Humans; Immunotherapy; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2007

Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21

Topics: Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Humans; Immunotherapy; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand

2007